Table of contents

  • Brand Names
  • Drug Combinations
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Substrate of
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Asmanex, Elocon, Mometason, Nasonex; Belgium: Elocom, Nasonex; Bulgaria: Elocom, Nasonex; Cyprus: Elocon, Movesan; Czech Republic: Asmanex, Elocom, Eztom, Momesalic, Nasonex; Denmark: Asmanex, Elocom, Elocon, Nasomet, Nasonex; Estonia: Asmanex, Elocon, Nasonex; Finland: Elocon, Nasonex; France: Nasonex; Germany: Asmanex, Ecural, Elocom, Elocon, Elovent, Momegalen, Mometason, Nasonex; Greece: Asmanex, Bioelementa, Ecelecort, Elocon, F-Din, Fremomet, Logren, Makiren, Metason, Mofur, Molken, Momecort, Mometasone, Movesan, Nasonex, Pharmecort, Prospiril, Yperod; Hungary: Asmanex, Atozon, Elocom, Nasonex; Ireland: Asmanex, Elocon, Nasonex; Italy: Altosone, Elocon, Nasonex, Rinelon; Latvia: Nasonex; Luxembourg: Asmanex, Elocom, Nasonex, Prospiril; Malta: Elocon, Nasonex; Netherlands: Asmanex, Elocon, Mometason, Nasonex; Poland: Asmanex, Elocom, Elosone, Momederm, Nasonex; Portugal: Asmanex, Desdek, Elocom, Elomet, Elovent, Mometasona, Nasomet, Prospiril; Romania: Asmanex, Atozon, Elocom, Nasonex; Slovakia: Elocom, Eztom, Mometason, Nasonex; Slovenia: Asmanex, Elocom, Nasonex; Spain: Elica, Elocom, Mometasona, Nasonex, Rinelón; Sweden: Asmanex, Demoson, Elocon, Mometason, Nasonex; UK: Asmanex, Elocon, Nasonex.

North America

Canada: Elocom, Mometasone, Nasonex; USA: Asmanex, Elocon, Mometasone, Nasonex.

Latin America

Argentina: Derimod, Elocón, Fenisona, Hexaler Bronquial, Hexaler Nasal, Metason, Momeplus, Nasonex; Brazil: Dermotil, Elocom, Mometasona, Nasonex, Topison; Mexico: Elica, Elomet, Elovent, Rinelón, Uniclar.


Japan: Fulmeta, Mysera.

Drug combinations

Mometasone and Formoterol

Mometasone and Salicylic Acid

Mometasone, Orbifloxacin, and Posaconazole


Mometasone Furoate: C~27~H~30~Cl~2~O~6~. Mw: 521.43. (1) Pregna-1,4-diene-3,20-dione, 9,21-dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methyl-, (11β,16α)-; (2) 9,21-Dichloro-11β,17-dihydroxy-16α-methylpregna-1,4-diene-3,20-dione 17-(2-furoate). CAS-83919-23-7 (1987).

Pharmacologic Category

Hormones and Synthetic Substitutes; Adrenals. EENT Preparations; Anti-inflammatory Agents; Corticosteroids. Skin and Mucous Membrane Agents; Anti-inflammatory Agents. Inhalant Corticosteroid (Oral). Nasal Corticosteroid. Topical Corticosteroid. (ATC-Code: D07AC13; D07XC03; R01AD09; R03BA07).

Mechanism of action

May depress formation, release, and activity of endogenous chemical mediators of inflammation (kinins, histamine, liposomal enzymes, prostaglandins). Inhibits margination and subsequent cell migration to area of injury, and also reverses dilatation and increased vessel permeability in the area, resulting in decreased access of cells to sites of injury.

Therapeutic use

Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Treatment of nasal symptoms of seasonal and perennial allergic rhinitis. Prevention of nasal symptoms associated with seasonal allergic rhinitis. Treatment of nasal polyps in adults. Maintenance treatment of asthma as prophylactic therapy or as supplement in asthma patients requiring oral corticosteroids for the purpose of decreasing or eliminating oral corticosteroid requirement.

Pregnancy and lactiation implications

Teratogenicity and intrauterine growth retardation reported in animal studies with some topical steroids. Hypoadrenalism may occur in infants born to women receiving corticosteroids during pregnancy. Inhaled corticosteroids considered first-line agents for treatment of persistent asthma during pregnancy. Excretion in breast milk unknown (use caution). Topical products should not be applied to nipples.

Unlabeled use


Hypersensitivity to mometasone or any component of the formulation. Treatment of acute bronchospasm (oral inhaler).

Warnings and precautions

May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal axis, particularly in younger children or in patients receiving high doses for prolonged periods. Bronchospasm may occur with wheezing after inhalation. Avoid nasal corticosteroid use in recent nasal septal ulcers, nasal surgery or nasal trauma until healing has occurred. Prolonged use of corticosteroids may increase incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Exposure to chickenpox should be avoided. Corticosteroids should not be used to treat ocular herpes simplex, cerebral malaria, or viral hepatitis. Prolonged treatment with corticosteroids associated with development of Kaposi’s sarcoma (case reports). Corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Pre-existing psychiatric conditions may be exacerbated by corticosteroid use. Supplemental steroids (oral or parenteral) may be needed during stress or severe asthma attacks. Not to be used in status asthmaticus or for relief of acute bronchospasm. Use with caution in heart failure (fluid retention and hypertension with long-term use), in diabetes mellitus (may alter glucose production/regulation leading to hyperglycemia), in gastrointestinal diseases (diverticulitis, peptic ulcer, ulcerative colitis) due to perforation risk; in hepatic impairment, including cirrhosis (fluid retention with long-term use), and in myasthenia gravis (exacerbation of symptoms). Use with caution following acute myocardial infarct (myocardial rupture), in cataracts and/or glaucoma (increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use), in osteoporosis or risk for osteoporosis, in renal impairment (fluid retention may occur), and in history of seizure disorder (adrenal crisis). Changes in thyroid status (metabolic clearance of corticosteroids increases in hyperthyroidism and decreases in hypothyroidism). Orally-inhaled and intranasal corticosteroids may cause reduction in growth velocity in pediatric patients. There have been reports of systemic corticosteroid withdrawal symptoms (e.g. joint/muscle pain, lassitude, depression) when withdrawing inhalation therapy. When transferring to oral inhaler, previously-suppressed allergic conditions (rhinitis, conjunctivitis, eczema) may be unmasked.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart